Expanded access, sometimes called compassionate use, can allow a patient with a serious or immediately life-threatening disease to receive an investigational medical product outside a clinical trial when regulatory criteria are met. It is a treatment-access mechanism, not marketing approval and not proof that the product works.
The distinction protects both accuracy and patients. Access can be ethically important precisely because evidence remains incomplete.
The pathway is for treatment, not research enrollment
Clinical trials are designed to answer research questions under a protocol. Expanded access primarily aims to diagnose, monitor, or treat a patient who lacks a comparable or satisfactory alternative and cannot obtain the investigational product through trial participation.
Data may still be collected and safety information must be reported, but access cases usually lack randomization, a concurrent comparator, standardized outcome assessment, and the sample size needed for reliable causal conclusions.
A favorable outcome after access can generate a hypothesis. It does not show what would have happened without treatment.
FDA weighs specific criteria
Federal regulations require, among other elements, that the patient or patients have a serious or immediately life-threatening disease or condition, no comparable or satisfactory alternative therapy, and no access to the product under a clinical trial. The potential benefit must justify the potential risks, and providing the product must not interfere with investigations that could support marketing approval or otherwise compromise development.
The sponsor or manufacturer must be willing to provide the product. FDA authorization cannot compel a company to supply it.
There are several access scales
Expanded access can cover:
- an individual patient, including emergency use;
- intermediate-size patient populations;
- widespread treatment use under a treatment IND or protocol.
The evidence and development context differ across these categories. A single-patient authorization should not be described as a general program available to everyone with the condition.
Emergency procedures can allow treatment to begin before the full written submission, with follow-up documentation required. “Emergency” modifies the timing of authorization; it does not remove oversight.
IRB and informed consent remain central
Expanded access generally requires institutional review board review and informed consent, with special procedures for emergencies. The treating physician assumes investigator responsibilities, including recordkeeping and safety reporting.
Consent should communicate that the product is investigational, risks may be unknown, benefit is uncertain, and alternatives exist or are limited. Payment and treatment costs should also be clear.
Authorization is permission to proceed under defined safeguards, not a recommendation that benefit is likely for a particular patient.
Safety reports are valuable but hard to interpret
People receiving expanded access may be sicker, use multiple therapies, or have conditions that themselves cause serious events. Attribution is difficult. At the same time, rare or unexpected toxicities can be important and must reach regulators and sponsors.
FDA has stated that safety information from expanded access is considered in context. The possibility of reporting obligations should not be transformed into a claim that the program functions like a controlled safety trial.
Cost recovery is regulated
Manufacturers generally cannot commercially sell an unapproved product through expanded access. FDA regulations permit recovery of certain direct costs when authorized and, for some broader programs, additional costs of making the product available.
Charging does not create commercial approval or establish product value. A report about access should not frame payment as evidence that a product is legally marketed.
Expanded access and Right to Try are different pathways
The federal Right to Try Act provides a separate route for certain eligible patients to access eligible investigational drugs without an FDA expanded-access application. It has its own eligibility and reporting framework.
Right to Try does not require a manufacturer to provide a product and does not make the product approved. State laws can differ, and treating institutions may have additional policies.
The pathways should be named correctly rather than grouped under “FDA compassionate approval.”
How to describe a public case
Accurate:
FDA authorized individual-patient expanded access to investigational product X. The authorization allowed treatment under an expanded-access IND and did not constitute marketing approval or evidence of efficacy.
Unsupported:
FDA approved product X after it cured the patient.
Even if the patient improved, temporal association, concurrent care, natural history, and outcome definition need evaluation.
A verification checklist
When reviewing an access claim, identify:
- the exact product and manufacturer;
- individual, intermediate, or treatment-program access;
- emergency or non-emergency procedure;
- condition and lack of trial eligibility;
- FDA and IRB status as publicly documented;
- treatment dates and concurrent therapies;
- prespecified monitoring and outcomes;
- adverse-event reporting;
- whether results were independently published;
- separate marketing-approval status.
Patient privacy will appropriately limit many details. Lack of a public case record should not be used to infer that authorization did or did not occur.
Bottom line
Expanded access can provide an investigational product to a patient facing serious disease and limited options. The authorization reflects a case-specific risk-benefit and access decision. It is not FDA approval and, by itself, cannot establish clinical effectiveness.
Sources
- U.S. Food and Drug Administration. Expanded Access.
- U.S. Food and Drug Administration. Expanded Access: Information for Physicians.
- Electronic Code of Federal Regulations. 21 CFR Part 312, Subpart I, Expanded Access.
- U.S. Food and Drug Administration. Expanded Access to Investigational Drugs for Treatment Use, Questions and Answers.
- U.S. Food and Drug Administration. Right to Try.
Continue reading
Editorial responsibility and corrections
Published by Serum Research. Sources checked October 1, 2026. This is educational material; no independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Read how we review evidence or send a correction.
For Research Use Only. Not for Human Consumption. This page does not provide instructions for medical use or establish the identity, quality, safety, or equivalence of a catalog material.